n 6 os  (Alomone Labs)

Journal: Biomedicines

Article Title: Activation of Voltage-Gated Na + Current by GV-58, a Known Activator of Ca V Channels

doi: 10.3390/biomedicines10030721

Figure Lengend Snippet: Comparisons of effects of GV-58, GV-58 plus ω-conotoxin MVIID, and GV-58 plus tetrodotoxin (TTX) on the peak amplitude of I Na recorded from GH 3 cells. Cells were immersed in Ca 2+ -free Tyrode’s solution containing 10 mM TEA, and the pipettes used were filled with Cs + -containing solution. Current amplitude was taken at the beginning of the brief depolarizing pulse from −80 to −10 mV. Each bar indicates the mean ± SEM (n = 8 for each bar). Of notice, the peak I Na in GH 3 cells is subject to inhibition by TTX but not by ω-conotoxin MVIID. * Significantly different from control ( p < 0.05) and ** Significantly different from GV-58 (3 μM) alone group ( p < 0.05). Statistical analyses were made by one-way ANOVA among different groups ( p < 0.05).

Article Snippet: GV-58 (1402821-41-3, CHEMBL2206242, SCHEMBL17628602, (2 R )-2-[(6-{[(5-methylthiophen-2-yl)methyl]amino}-9-propyl-9H-purin-2-yl)amino]butan-1-ol, C 18 H 26 N 6 OS, https://pubchem.ncbi.nlm.nih.gov/compound/71463101 , accessed on 1 December 2022), ω-conotoxin MVIID, and tetrodotoxin (TTX) were acquired from Alomone Labs (Genechain, Kaohsiung, Taiwan), while 4-aminopyridine, E-4031, nimodipine, ranolazine, retinoic acid, riluzole, and tetraethylammonium chloride (TEA) were from Sigma-Aldrich (Merck, Taipei, Taiwan).

Techniques: Inhibition

Journal: Biomedicines

Article Title: Activation of Voltage-Gated Na + Current by GV-58, a Known Activator of Ca V Channels

doi: 10.3390/biomedicines10030721

Figure Lengend Snippet: Effects of GV−58 on spontaneous action potentials (APs) recorded from GH 3 cells. Cells were bathed in normal Tyrode’s solution, and the recording pipettes were filled with K + −containing solution. When whole−cell configuration was established, we switched to the whole−cell current clamp recordings to measure changes in membrane potential, as current was set at zero. ( A ) Representative potential traces achieved in the absence (upper) and presence of 1 μM GV−58 (middle) or 3 μM GV−58 (lower). ( B ) Summary graph demonstrating effect of ω−conotoxin MVIID, GV−58, and GV−58 plus ranolazine (Ran) on the firing frequency of APs in GH 3 cells (mean ± SEM; n = 8). * Significantly different from control ( p < 0.05) and ** Significantly different from GV−58 (3 μM) alone group ( p < 0.05). Statistical analyses were made in one−way ANOVA among different groups ( p < 0.05).

Article Snippet: GV-58 (1402821-41-3, CHEMBL2206242, SCHEMBL17628602, (2 R )-2-[(6-{[(5-methylthiophen-2-yl)methyl]amino}-9-propyl-9H-purin-2-yl)amino]butan-1-ol, C 18 H 26 N 6 OS, https://pubchem.ncbi.nlm.nih.gov/compound/71463101 , accessed on 1 December 2022), ω-conotoxin MVIID, and tetrodotoxin (TTX) were acquired from Alomone Labs (Genechain, Kaohsiung, Taiwan), while 4-aminopyridine, E-4031, nimodipine, ranolazine, retinoic acid, riluzole, and tetraethylammonium chloride (TEA) were from Sigma-Aldrich (Merck, Taipei, Taiwan).

Techniques: